Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034203 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
A Phase 2 study of Rheumatoid Arthritis, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00034203 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Xoma (US). The trial reports 20 study locations across 6 states.
The verdict
NCT00034203, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
Conditions Studied
Interventions
- DRUG efalizumab
Study Locations (20)
California
- University of California at San Diego - La Jolla
- UCLA - Los Angeles
- Wallace Rheumatic Study Center - Los Angeles
- Boling Clinical Trials - Rancho Cucamonga
- Desert Medical Advances - Rancho Mirage
- The San Diego Arthritis and Osteoporosis Medical Clinic - San Diego
- Pacific Arthritis Center - Santa Maria
Florida
- Clinical Research of West Florida - Clearwater
- The Center for Rheumatology, Immunology and Arthritis - Fort Lauderdale
- Anchor Research Center - Naples
- Rheumatology Associates of Central Florida - Orlando
- nTouch Research Corporation - St. Petersburg
Alabama
- University of Alabama at Birmingham - Birmingham
- Rheumatology Associates of North Alabama - Huntsville
Arizona
- Arizona Arthritis Research, PLC - Paradise Valley
- Advanced Clinical Therapeutics, LLC - Tucson
Arkansas
- NEA Clinic - Jonesboro
- Little Rock Diagnostic Clinic - Little Rock
Connecticut
- Northeast Clinical Research, LLC - Hamden
- Clinical Research Consultants, Inc. - Trumbull
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034203
The ClinicalTrials.gov registry entry for NCT00034203 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which efalizumab is the first listed.
NCT00034203 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00034203 about?
NCT00034203 is a clinical study titled "Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.". The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
What is the current status of trial NCT00034203?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-04. Estimated completion is 2003-08.
What conditions does trial NCT00034203 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00034203?
The interventions under investigation include: efalizumab (DRUG).
Who is sponsoring clinical trial NCT00034203?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034203 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.